Membrane-acting biomimetic peptoids against visceral leishmaniasis

FEBS Open Bio. 2023 Mar;13(3):519-531. doi: 10.1002/2211-5463.13562. Epub 2023 Feb 7.

Abstract

Visceral leishmaniasis (VL) is among the most neglected tropical diseases in the world. Drug cell permeability is essential for killing the intracellular residing parasites responsible for VL, making cell-permeating peptides a logical choice to address VL. Unfortunately, the limited biological stability of peptides restricts their usage. Sequence-specific oligo-N-substituted glycines ('peptoids') are a class of peptide mimics that offers an excellent alternative to peptides in terms of ease of synthesis and good biostability. We tested peptoids against the parasite Leishmania donovani in both forms, that is, intracellular amastigotes and promastigotes. N-alkyl hydrophobic chain addition (lipidation) and bromination of oligopeptoids yielded compounds with good antileishmanial activity against both forms, showing the promise of these antiparasitic peptoids as potential drug candidates to treat VL.

Keywords: antimicrobial; antiparasitic; leishmania; peptide mimetic; peptoid.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biomimetics
  • Humans
  • Leishmania donovani*
  • Leishmaniasis, Visceral* / drug therapy
  • Leishmaniasis, Visceral* / parasitology
  • Peptides
  • Peptoids* / pharmacology
  • Peptoids* / therapeutic use

Substances

  • Peptoids
  • Peptides